文献速递血液净化与透析

血液透析患者对SARS-CoV-2 mRNA疫苗体液与细胞免疫应答的预测因素及动态变化

Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study.
PubMed 文献 · J Am Soc Nephrol · 2021-12-01

这项前瞻性多中心观察研究纳入543例血液透析患者和75名健康志愿者,评估接种BNT162b2或mRNA-1273疫苗后4~5周和8~9周的抗体与T细胞应答。结果显示,透析患者的体液免疫应答不完整且延迟,细胞免疫应答减弱;mRNA-1273在抗体和QuantiFERON应答上均优于BNT162b2。多因素分析确定了COVID-19感染史、疫苗类型、免疫抑制剂使用等独立预测因素。

要点

  • 透析患者接种mRNA疫苗后体液免疫不完整且延迟,细胞免疫应答减弱。
  • mRNA-1273在抗体滴度和QuantiFERON应答上均优于BNT162b2。
  • 高剂量mRNA疫苗可能改善透析患者受损的免疫应答。

核心结论

  • 血液透析患者对SARS-CoV-2 mRNA疫苗的体液免疫应答不完整且延迟,细胞免疫应答减弱。
  • mRNA-1273的免疫原性优于BNT162b2,可能与其mRNA剂量较高有关。
  • 高剂量疫苗可能改善透析患者受损的SARS-CoV-2疫苗免疫应答。

研究设计与样本

  • 前瞻性多中心观察研究,纳入543例血液透析患者和75名健康志愿者。
  • 在接种BNT162b2或mRNA-1273疫苗后4或5周及8或9周评估免疫应答。
  • 检测抗SARS-CoV-2刺突抗体,并以QuantiFERON法检测外周血淋巴细胞经糖蛋白刺激后的IFN-γ分泌评估T细胞应答。

主要发现

  • 与健康志愿者相比,透析患者的体液免疫应答不完整且延迟,细胞免疫应答减弱。
  • 两个时间点mRNA-1273接种者的抗体几何平均滴度均显著高于BNT162b2接种者。
  • 8或9周时达到4160 AU/ml阈值者比例:mRNA-1273组53.6% vs BNT162b2组31.8%,P<0.0001。
  • 两个时间点mRNA-1273接种者的QuantiFERON应答中位数均显著高于BNT162b2接种者。
  • 8或9周时达到0.15 IU/ml阈值者比例:mRNA-1273组64.4% vs BNT162b2组46.9%,P<0.0001。

关键数值与推荐

  • 抗体高中和滴度对应阈值为4160 AU/ml。
  • QuantiFERON应答阈值为0.15 IU/ml。
  • 多因素分析确定的体液和细胞应答独立预测因素包括:COVID-19感染史、疫苗类型、免疫抑制剂使用、血清白蛋白、淋巴细胞计数、乙肝疫苗无应答状态和透析龄。

临床怎么用

  • 透析患者接种SARS-CoV-2 mRNA疫苗时,可优先考虑mRNA-1273以增强免疫应答。
  • 对使用免疫抑制剂、低白蛋白、低淋巴细胞计数、乙肝疫苗无应答及长透析龄患者应关注免疫应答不足。
  • 接种后免疫应答评估可参考抗体阈值4160 AU/ml和QuantiFERON阈值0.15 IU/ml。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preliminary evidence suggests patients on hemodialysis have a blunted early serological response to SARS-CoV-2 vaccination. Optimizing the vaccination strategy in this population requires a thorough understanding of predictors and dynamics of humoral and cellular immune responses to different SARS-CoV-2 vaccines. METHODS: This prospective multicenter study of 543 patients on hemodialysis and 75 healthy volunteers evaluated the immune responses at 4 or 5 weeks and 8 or 9 weeks after administration of the BNT162b2 or mRNA-1273 vaccine, respectively. We assessed anti-SARS-CoV-2 spike antibodies and T cell responses by IFN-γ secretion of peripheral blood lymphocytes upon SARS-CoV-2 glycoprotein stimulation (QuantiFERON assay) and evaluated potential predictors of the responses. RESULTS: Compared with healthy volunteers, patients on hemodialysis had an incomplete, delayed humoral immune response and a blunted cellular immune response. Geometric mean antibody titers at both time points were significantly greater in patients vaccinated with mRNA-1273 versus BNT162b2, and a larger proportion of them achieved the threshold of 4160 AU/ml, corresponding with high neutralizing antibody titers in vitro (53.6% versus 31.8% at 8 or 9 weeks, P <0.0001). Patients vaccinated with mRNA-1273 versus BNT162b2 exhibited significantly greater median QuantiFERON responses at both time points, and a larger proportion achieved the threshold of 0.15 IU/ml (64.4% versus 46.9% at 8 or 9 weeks, P <0.0001). Multivariate analysis identified COVID-19 experience, vaccine type, use of immunosuppressive drugs, serum albumin, lymphocyte count, hepatitis B vaccine nonresponder status, and dialysis vintage as independent predictors of the humoral and cellular responses. CONCLUSIONS: The mRNA-1273 vaccine's greater immunogenicity may be related to its higher mRNA dose. This suggests a high-dose vaccine might improve the impaired immune response to SARS-CoV-2 vaccination in patients on hemodialysis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Van Praet J, Reynders M, De Bacquer D, et al. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. J Am Soc Nephrol. 2021. PMID: 34588184. doi:10.1681/ASN.2021070908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。